Citations

Showing 10 of 108104 citations.

Wilson disease‐related cirrhosis is associated with increased odds of hemolytic anemia
Aby, Elizabeth S. , Palmer, William C. , Kröner, Paul T. , Wijarnpreecha, Karn

Mayo Clinic

Journal of Evidence-Based Medicine | April 13, 2022 | Volume: 15 | Issue: 1 | Pages: 15-18

10.1111/jebm.12463 | PMID 35416435 Get It

Alopecia in children undergoing chemotherapy, radiation, and hematopoietic stem cell transplantation: Scoping review and approach to management
Kessler, Stephen, Marzooq, Ali, Sood, Arun, Beebe, Kristen , Walsh, Alexandra , Montoya, Liliana , Price, Harper , Price, Harper N , Sood, Arun

Mayo Clinic

Pediatric Dermatology | April 13, 2022 | Volume: 39 | Issue: 3 | Pages: 354-362

10.1111/pde.14995 | PMID 35416328 Get It

AbstractAlopecia is a common sequela in children undergoing chemotherapy, radiation, and hematopoietic stem cell transplantation. In most cases, this is a transient state in which full hair regrowth eventually occurs, but permanent or persistent alopecia, defined as the presence of incomplete hair regrowth more than 6 months after cessation of treatment, is possible and can be psychologically distressing. We sought to characterize the risk factors that can lead to permanent alopecia following the aforementioned treatments in pediatric populations, as well as diagnostic and treatment options that may be considered, as part of a scoping review of the literature. A general algorithm for approaching these patients was developed based on our findings.
Quantitative analysis of visually reviewed normal scalp EEG predicts seizure freedom following anterior temporal lobectomy
Varatharajah, Yogatheesan , Brinkmann, Benjamin H. , Morita‐Sherman, Marcia , Fitzgerald, Zachary , Vegh, Deborah , Nair, Dileep , Burgess, Richard C. , Cendes, Fernando , Jehi, Lara , Joseph, Boney , Brinkmann, Benjamin H , Fitzgerald, Zachary , Cendes, Fernando , Jehi, Lara , Nair, Dileep R , Joseph, Boney , Morita, Márcia Elisabete , Worrell, Gregory A.

Mayo Clinic

Epilepsia | April 13, 2022 | Volume: 63 | Issue: 7 | Pages: 1630-1642

10.1111/epi.17257 | PMID 35416285 Get It

Abstract Objective Anterior temporal lobectomy (ATL) is a widely performed and successful intervention for drug‐resistant temporal lobe epilepsy (TLE). However, up to one third of patients experience seizure recurrence within 1 year after ATL. Despite the extensive literature on presurgical electroencephalography (EEG) and magnetic resonance imaging (MRI) abnormalities to prognosticate seizure freedom following ATL, the value of quantitative analysis of visually reviewed normal interictal EEG in such prognostication remains unclear. In this retrospective multicenter study, we investigate whether machine learning analysis of normal interictal scalp EEG studies can inform the prediction of postoperative seizure freedom outcomes in patients who have undergone ATL. Methods We analyzed normal presurgical scalp EEG recordings from 41 Mayo Clinic (MC) and 23 Cleveland Clinic (CC) patients. We used an unbiased automated algorithm to extract eyes closed awake epochs from scalp EEG studies that were free of any epileptiform activity and then extracted spectral EEG features representing (a) spectral power and (b) interhemispheric spectral coherence in frequencies between 1 and 25 Hz across several brain regions. We analyzed the differences between the seizure‐free and non–seizure‐free patients and employed a Naïve Bayes classifier using multiple spectral features to predict surgery outcomes. We trained the classifier using a leave‐one‐patient‐out cross‐validation scheme within the MC data set and then tested using the out‐of‐sample CC data set. Finally, we compared the predictive performance of normal scalp EEG‐derived features against MRI abnormalities. Results We found that several spectral power and coherence features showed significant differences correlated with surgical outcomes and that they were most pronounced in the 10–25 Hz range. The Naïve Bayes classification based on those features predicted 1‐year seizure freedom following ATL with area under the curve (AUC) values of 0.78 and 0.76 for the MC and CC data sets, respectively. Subsequent analyses revealed that (a) interhemispheric spectral coherence features in the 10–25 Hz range provided better predictability than other combinations and (b) normal scalp EEG‐derived features provided superior and potentially distinct predictive value when compared with MRI abnormalities (>10% higher F1 score). Significance These results support that quantitative analysis of even a normal presurgical scalp EEG may help prognosticate seizure freedom following ATL in patients with drug‐resistant TLE. Although the mechanism for this result is not known, the scalp EEG spectral and coherence properties predicting seizure freedom may represent activity arising from the neocortex or the networks responsible for temporal lobe seizure generation within vs outside the margins of an ATL.
Development of a Lyophilized Off-the-Shelf Mesenchymal Stem Cell-Derived Acellular Therapeutic
Driscoll, Julia , Yan, Irene K. , Patel, Tushar

Mayo Clinic

Pharmaceutics | April 13, 2022 | Volume: 14 | Issue: 4 | Pages: 849

10.3390/pharmaceutics14040849 | PMID 35456683 Get It

The therapeutic activities elicited by mesenchymal stem cells (MSC) are in part mediated through paracrine action by the release of extracellular vesicles (EV) and secreted proteins. Collectively, these MSC-derived factors, referred to as the secretome product (SP), are intrinsically therapeutic and represent an attractive alternative to cell-based therapies. Herein, we developed a lyopreservation protocol to extend the shelf-life of the MSC-SP without compromising the structural or functional integrity of the vesicular components. The SP isolated from normoxia- and anoxia-exposed MSC elicited protective effects in an in vitro model of oxidative injury and the bioactivity was retained in the lyophilized samples. Three separate formulations of MSC-SP were isolated by tangential flow filtration using sucrose, trehalose, and mannitol as lyoprotectant agents. The MSC-SPs were lyophilized using a manifold protocol and the structural and functional integrity were assessed. The trehalose formulation of SP exhibited the highest EV and protein recovery after manifold-based lyophilization. To facilitate development as a therapeutic, a shelf lyophilization protocol was developed which markedly enhanced the recovery of EV and proteins. In conclusion, lyophilization represents an efficient method to preserve the structural and functional integrity of the MSC-SP and can be used to develop an off-the-shelf therapeutic.
Capsaicin as an amphipathic modulator of NaV1.5 mechanosensitivity
Cowan, Luke M. , Rusinova, Radda , Farrugia, Gianrico , Beyder, Arthur , Strege, Peter R. , Beyder, Arthur , Cowan, Luke M , Andersen, Olaf Sparre

Mayo Clinic

Channels | April 12, 2022 | Volume: 16 | Issue: 1 | Pages: 9-26

10.1080/19336950.2022.2026015 | PMID 35412435 Get It

Outcomes after biochemical or clinical progression in patients with multiple myeloma
Goldman‐Mazur, Sarah , Kapoor, Prashant , Lacy, Martha Q. , Gertz, Morie A. , Buadi, Francis K. , Hayman, Suzanne R. , Dingli, David , Kourelis, Taxiarchis , Warsame, Rahma , Binder, Moritz , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Visram, Alissa , Dispenzieri, Angela , Lacy, Martha Q , Gertz, Morie A , Buadi, Francis K , Kourelis, Taxiarchis , Warsame, Rahma , Muchtar, E , Leung, Nelson , Binder, Moritz , Fonder, Amie , Hwa, Yi Lisa, Kumar, Shaji K , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Muchtar, Eli , Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | April 12, 2022 | Volume: 7 | Issue: 6 | Pages: 909-917

10.1182/bloodadvances.2022007082 | PMID 35413102 Get It

Abstract Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time of biochemical progression (BP) improves the outcomes compared with initiating therapy at the clinical progression (CP) stage. Here, we retrospectively assessed 1347 patients with relapsed MM. Most progressions were BP (60.4%); 39.6% had CP. The most prevalent symptoms at relapse were new or evolving bone disease (80.9%), anemia (38.0%), and renal failure (12.7%). Patients with BP had longer median time from second-line treatment to the next treatment compared with patients who had CP (17.0 vs 9.6 months; P < .001) as well as longer median overall survival from first relapse (59.4 vs 26.2 months; P < .001). Male sex (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.02-2.18; P = .04), plasma cell labeling index ≥2% (OR, 1.58; 95% CI, 1.02-2.45; P = .04), and extramedullary disease at diagnosis (OR, 1.84; 95% CI, 1.08-3.13; P = .03) were associated with higher risk of CP, whereas very good partial remission or better had decreased risk of CP (OR, 0.62; 95% CI, 0.43-0.91; P = .02). To conclude, patients with CP have inferior postprogression outcomes compared with patients who have BP. Patients with deeper response to first-line therapy are less likely to develop CP. The presence of a specific CRAB (C, hypercalcemia; R, renal failure; A, anemia; B, bone disease) symptom at diagnosis predicts for the development of similar CRAB symptoms at relapse.
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Adashek, Jacob J. , Menta, Arjun K. , Reddy, Neha K. , Desai, Aakash , Roszik, Jason , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Molecular Cancer Therapeutics | April 12, 2022 | Volume: 21 | Issue: 6 | Pages: 871-878

10.1158/1535-7163.mct-21-0950 | PMID 35413124 Get It

Abstract BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation—positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malignancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.
The Impact of Health Information Technology for Early Detection of Patient Deterioration on Mortality and Length of Stay in the Hospital Acute Care Setting: Systematic Review and Meta-Analysis
Lipatov, Kirill , Pinevich, Yuliya , Tekin, Aysun , Pickering, Brian W. , Barwise, Amelia , Herasevich, Svetlana , Lindroth, Heidi , Barwise, Amelia K , Tekin, Aysun , Herasevich, Vitaly

Mayo Clinic

Critical Care Medicine | April 12, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ccm.0000000000005554 | PMID 35412476 Get It

Objective: To evaluate the impact of health information technology (HIT) for early detection of patient deterioration on patient mortality and length of stay (LOS) in acute care hospital settings. Data Sources: We searched MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from 1990 to January 19, 2021. Study Selection: We included studies that enrolled patients hospitalized on the floor, in the ICU, or admitted through the emergency department. Eligible studies compared HIT for early detection of patient deterioration with usual care and reported at least one end point of interest: hospital or ICU LOS or mortality at any time point. Data Extraction: Study data were abstracted by two independent reviewers using a standardized data extraction form. Data Synthesis: Random-effects meta-analysis was used to pool data. Among the 30 eligible studies, seven were randomized controlled trials (RCTs) and 23 were pre-post studies. Compared with usual care, HIT for early detection of patient deterioration was not associated with a reduction in hospital mortality or LOS in the meta-analyses of RCTs. In the meta-analyses of pre-post studies, HIT interventions demonstrated a significant association with improved hospital mortality for the entire study cohort (odds ratio, 0.78 [95% CI, 0.70–0.87]) and reduced hospital LOS overall. Conclusions: HIT for early detection of patient deterioration in acute care settings was not significantly associated with improved mortality or LOS in the meta-analyses of RCTs. In the meta-analyses of pre-post studies, HIT was associated with improved hospital mortality and LOS; however, these results should be interpreted with caution. The differences in patient outcomes between the findings of the RCTs and pre-post studies may be secondary to confounding caused by unmeasured improvements in practice and workflow over time.
Successful graded-dose challenge of the Janssen vaccine against SARS-CoV-2 in a high-risk patient
Jhawar, Nikita , Joundi, H, Gonzalez-Estrada, A, Jhawar, N

Mayo Clinic

QJM: An International Journal of Medicine | April 12, 2022 | Volume: 115 | Issue: 5 | Pages: 329-330

10.1093/qjmed/hcac099 | PMID 35412631 Get It